Elisabeth Lackner

Elisabeth Lackner is an accomplished professional in the healthcare and life sciences sectors, currently serving as the Chief Executive Officer at CRS Clinical Research Services since March 2024, leading a multi-indication CRO that specializes in early-phase clinical trials. In addition to this role, Elisabeth is a Senior Advisor at Arthur D. Little and Marinomed Biotech AG, where Elisabeth also holds a position as a Board Member. Elisabeth has significant experience as a Senior Advisor in healthcare and life sciences, and as a member of the Board of Advisors at Rivean Capital. Previously, Elisabeth served as CSO and a member of the Operating Board at Element Materials Technology, General Manager at D&A Pharma, and Managing Director of GBA Gesellschaft für Bioanalytik mbH. Additionally, Elisabeth has held the CEO position at GBA Pharma and ABF Pharmaceutical Services, contributing to diverse aspects of pharmaceutical services, including labeling, packaging, and bio sample storage. Educationally, Elisabeth has an MSc in Tumor Biology and a PhD in Oncology from the University of Vienna, along with a degree in Pharmacy.